Ȩ > Publication > ±¹ Á¦

ÀÛ¼ºÀÚ :      ÀÛ¼ºÀÏ :     2009-02-26 (14:02:09)
À̸ÞÀÏ :      Á¶È¸¼ö :     41342
ȨÆäÀÌÁö :      ¾ÆÀÌÇÇ :     ***.***.***.***
±ÛÁ¦¸ñ :     Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol.
 
 J Am Soc Nephrol. 1997 Mar;8(3):426-35.

Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol.

Research Division, Joslin Diabetes Center, Boston, MA 02215, USA.

Because d-alpha-tocopherol (vitamin E) has been shown to decrease diacylglycerol (DAG) levels and prevent the activation of protein kinase C (PKC), which is associated with retinal and renal dysfunctions in diabetes, the study presented here characterized the effect of d-alpha-tocopherol treatment to prevent glomerular hyperfiltration and increased albuminuria as well as PKC activities in streptozotocin (STZ)-induced diabetic rats. Two weeks after the induction of diabetes, total DAG content and PKC activity in glomeruli were significantly increased in diabetic rats by 106.4 +/- 16.8% and 66.4 +/- 8.4%, respectively, compared with control rats. Intraperitoneal injection of d-alpha-tocopherol (40 mg/kg of body weight) every other day prevented the increases in total DAG content and PKC activity in glomeruli of diabetic rats. Glomerular filtration rate (GFR) and filtration fraction (FF) were significantly elevated to 4.98 +/- 0.34 mL/min and 0.36 +/- 0.05, respectively, in diabetic rats, compared with 2.90 +/- 0.14 mL/min and 0.25 +/- 0.02, respectively, in control rats. These hemodynamic abnormalities in diabetic rats were normalized to 2.98 +/- 0.09 mL/min and 0.24 +/- 0.01, respectively, by d-alpha-tocopherol. Albuminuria in 10-wk diabetic rats was significantly increased to 9.1 +/- 2.2 mg/day compared with 1.2 +/- 0.3 mg/day in control rats, whereas d-alpha-tocopherol treatment improved albumin excretion rate to 2.4 +/- 0.6 mg/day in diabetic rats. To clarify the mechanism of d-alpha-tocopherol's effect on DAG-PKC pathway, the activity and protein levels of DAG kinase alpha and gamma, which metabolize DAG to phosphatidic acid, were examined. Treatment with d-alpha-tocopherol increased DAG kinase activity in the glomeruli of both control and diabetic rats, by 22.6 +/- 3.6% and 28.5 +/- 2.3% respectively, although no differences were observed in the basal DAG kinase activity between control and diabetic rats. Because immunoblotting studies did not exhibit any difference in the protein levels of DAG kinase alpha and gamma, the effect of d-alpha-tocopherol is probably modulating the enzyme kinetics of DAG kinase. These findings suggest that the increases in DAG-PKC pathway play an important role for the development of glomerular hyperfiltration and increased albuminuria in diabetes and that d-alpha-tocopherol treatment could be preventing early changes of diabetic renal dysfunctions by normalizing the increases in DAG and PKC levels in glomerular cells.

PMID: 9071711 [PubMed - indexed for MEDLINE]

 
 
 
name :
password :
  comment :
 
 
ÀÌÀü±Û ¸ñ·Ï »õ±Û¾²±â ÀÀ´ä±Û¾²±â ±Û¼öÁ¤Çϱ⠱ÛÁö¿ì±â ´ÙÀ½±Û



96 Metastatic pleural cancer in radionuclide angiocardiography. A pulmonary time-activity curve mimicki  2009.02.2745374
95 Plasma type IV collagen and fibronectin concentrations in diabetic patients with microangiopathy  2009.02.2651537
Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol.  2009.02.2641342
93 d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kin  2009.02.2636630
92 Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose- and angiotensin II-  2009.02.2639614
91 Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes.  2009.02.2646639
90 The effect of parental imprinting on the INS-IGF2 locus of Korean type I diabetic patients.  2009.02.2640688
89 Usefulness of lumbar AP spine DXA for measuring the percentage of perilumbar regional fat and predic  2009.02.2638392
88 Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes  2009.02.2644833
87 Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell prolifer  2009.02.2646038
86 Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia.  2009.02.2645716
85 Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and  2009.02.2642534
84 Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in  2009.02.2643932
83 Postprandial hypertriglyceridemia-induced endothelial dysfunction in healthy subjects is independent  2009.02.2644336
82 Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea  2009.02.2640717
81 Oleic acid induces endothelin-1 expression through activation of protein kinase C and NF-kappa B.  2009.02.2640468
80 Modulation of Sp1-dependent transcription by a cis-acting E2F element in dhfr promoter.  2009.02.2639423
79 Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by in  2009.02.2639436
78 Functional characterization of the human resistin promoter with adipocyte determination- and differe  2009.02.2642285
77 Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through di  2009.02.2641936
 1 [2][3][4][5]
¸ñ·Ï »õ±Û¾²±â